Drug
HuMax-IL8 clinical trials
Also written BMS-986253.
- studies test it
- 7
- open now
- 0
- in phase 3
- 0
- first study started
- 2015
How studies write it
Studies that test it under each name
Name
Development codes
Studies by the year they started
7 studies that test it; most in 2018 (2)
| Year | Studies |
|---|---|
| 2015 | 1 |
| 2016 | 1 |
| 2018 | 2 |
| 2020 | 2 |
| 2021 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 2 · Other 5
Bristol-Myers Squibb (2) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (1) · Icahn School of Medicine at Mount Sinai (1) · Yana Najjar (1) · Mark Stein (1) · Columbia University (1)
Often tested with
Tested in the same studies.
Nivolumab (2) · Cyclophosphamide (1) · Urelumab (1) · BMS-813160 (1) · Ipilimumab (1)
Studies
Open first, then newest update. How each study uses HuMax-IL8 is read from its arms, and is right about nine times in ten.
Testing it · 7
- Nivolumab and BMS-986253 for Hormone-Sensitive Prostate Cancer (MAGIC-8)CompletedPhase 1/2Mark SteinNCT03689699Written as BMS-986253
- Platform Study of Neoadjuvant and Adjuvant Immunotherapy for Patients With Resectable Adenocarcinoma of the PancreasActive, not recruitingPhase 2Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNCT02451982Written as BMS-986253
- Neoadjuvant Nivolumab With CCR2/5-inhibitor or Anti-IL-8) for Non-small Cell Lung Cancer (NSCLC) or Hepatocellular Carcinoma (HCC)Active, not recruitingPhase 2Icahn School of Medicine at Mount SinaiNCT04123379Written as BMS-986253
- Safety of SBRT With Anti-PD1 and Anti-IL-8 for the Treatment of Multiple Metastases in Advanced Solid Tumors and MelanomaActive, not recruitingPhase 1Yana NajjarNCT04572451Written as BMS-986253
- A Study of BMS-986253 in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Advanced CancersCompletedPhase 1/2Bristol-Myers SquibbNCT03400332Written as BMS-986253
- Anti-Interleukin-8 (Anti-IL-8) for Patients With COVID-19TerminatedPhase 2Columbia UniversityNCT04347226Written as BMS-986253
- HuMax-IL8 (Interleukin8) in Patients With Advanced Malignant Solid TumorsCompletedPhase 1Bristol-Myers SquibbNCT02536469Written as HuMax-IL8
Given in every arm · 3 — HuMax-IL8 is usual care beside what is tested
- Neoadjuvant Immune Checkpoint Inhibition and Novel IO Combinations in Early-stage Colon CancerRecruitingPhase 2The Netherlands Cancer InstituteNCT03026140Written as BMS-986253
- Neoadjuvant Targeting of Myeloid Cell Populations in Combination With Nivolumab in Head & Neck CaActive, not recruitingPhase 2Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNCT04848116Written as HuMax-IL8
- BMS-986253 in Myelodysplastic SyndromesTerminatedPhase 1/2National Cancer Institute (NCI)NCT05148234Written as BMS-986253
Codes
What other systems call HuMax-IL8 · ClinicalTrials.gg INT001395
- MeSH (NLM) C000709704HuMax-IL8Confirmed ClinicalTrials.gov, NLM
- UNII (FDA) N0YWS8X3S9ADAKITUGConfirmed FDA, NLM
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000709704 | HuMax-IL8 | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | N0YWS8X3S9 | ADAKITUG | Confirmed FDA, NLM |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.